Last updated: August 1, 2026
Fibricor is the U.S. brand name for fenofibric acid delayed-release tablets, a fibrate used with diet to treat severe hypertriglyceridemia and primary hypercholesterolemia or mixed dyslipidemia. Its commercial position is weak because the product competes with generic fenofibric acid, fenofibrate, statins, prescription omega-3 products and newer triglyceride-lowering therapies. No active late-stage clinical development program or material patent barrier supports a branded growth thesis.
What is Fibricor and what is it approved to treat?
Fibricor contains fenofibric acid, the active metabolite of fenofibrate. The product is administered orally as delayed-release tablets in 35 mg and 105 mg strengths. FDA labeling covers two principal uses:
| Indication |
Fibricor role |
| Severe hypertriglyceridemia |
Adjunct to diet for adults with markedly elevated triglycerides |
| Primary hypercholesterolemia or mixed dyslipidemia |
Adjunct to diet when LDL cholesterol and triglycerides are elevated |
The product is not approved as cardiovascular-risk-reduction therapy. The FDA label states that the effect of Fibricor on cardiovascular morbidity and mortality has not been established.[1]
Fibricor lowers triglycerides and can increase high-density lipoprotein cholesterol. Its effect on low-density lipoprotein cholesterol is variable, particularly in patients with severe hypertriglyceridemia. The product is contraindicated in patients with severe renal impairment, active liver disease, gallbladder disease and severe hypersensitivity to fenofibric acid or fenofibrate.[1]
What are the latest Fibricor clinical-trial updates?
Fibricor has no visible current late-stage clinical-trial program directed toward a new indication, formulation or label expansion. The clinical evidence supporting the product is based primarily on historical phase 3 lipid trials and the regulatory review underlying its original approval.
Which clinical studies supported Fibricor approval?
FDA labeling reports placebo-controlled studies in patients with primary hypercholesterolemia or mixed dyslipidemia and in patients with severe hypertriglyceridemia. The trials evaluated changes in triglycerides, LDL cholesterol, total cholesterol and HDL cholesterol over short treatment periods, generally lasting several weeks.[1]
The studies demonstrated lipid-modifying activity but were not designed to establish reductions in cardiovascular events. That distinction limits Fibricor's positioning against statins and newer agents supported by cardiovascular-outcomes data.
Are there active Fibricor trials on ClinicalTrials.gov?
No material active interventional program specifically centered on the Fibricor brand is established in the public clinical-trial record through the latest broadly available data. Research involving fenofibric acid or fibrates may continue in academic or combination-therapy settings, but that activity does not create a meaningful branded Fibricor development pipeline.
The relevant clinical questions have shifted from simple triglyceride reduction to:
- Cardiovascular outcomes in patients with residual hypertriglyceridemia
- Combination use with statins
- Renal and hepatic safety
- Pancreatitis prevention in very severe hypertriglyceridemia
- Comparisons with prescription omega-3 products and newer metabolic therapies
What is the FDA regulatory status of Fibricor?
Fibricor was approved through an FDA new drug application for fenofibric acid delayed-release tablets. Its labeling identifies the product as an adjunct to diet rather than a replacement for statin therapy where statins are clinically indicated.[1]
| Regulatory issue |
Status |
| Active ingredient |
Fenofibric acid |
| Dosage form |
Delayed-release tablet |
| U.S. strengths |
35 mg and 105 mg |
| FDA pathway |
New drug application |
| Main therapeutic area |
Dyslipidemia and severe hypertriglyceridemia |
| Cardiovascular-outcomes indication |
None |
| Pediatric indication |
Not established in the product label |
| Generic competition |
Present or commercially available in the U.S. market |
| Current pipeline |
No material Fibricor-specific late-stage program identified |
The product label requires attention to renal function, liver tests and muscle toxicity. Concomitant use with statins, particularly in patients with renal impairment or other risk factors, can increase the risk of myopathy and rhabdomyolysis.[1]
What patents protect Fibricor and when does Fibricor lose exclusivity?
Fibricor's principal commercial protection has expired or no longer creates a meaningful barrier to generic competition. The active ingredient, fenofibric acid, is a mature small molecule, and the product has faced generic competition based on abbreviated new drug applications.
What is the Orange Book status of Fibricor?
The Orange Book historically listed Fibricor-related patents and regulatory exclusivity information associated with the approved product. The relevant listing period has passed, and Fibricor does not have a commercially significant unexpired patent estate comparable to recently launched specialty drugs.[2]
The key intellectual-property categories were:
| IP category |
Commercial relevance |
| Fenofibric acid composition |
Limited because the active ingredient is mature |
| Delayed-release tablet formulation |
Historical relevance; weak after generic approvals |
| Method-of-use claims |
Narrow and largely expired or vulnerable to label carve-outs |
| Manufacturing processes |
Potentially relevant to suppliers but not a broad market barrier |
| Brand and trademark |
Does not block generic substitution |
A precise current Orange Book listing should be checked against the latest FDA database record because product listings can change when NDAs are discontinued, transferred or updated.[2] The practical conclusion is unchanged: patent expiry and generic availability have removed the primary U.S. exclusivity protections.
What formulation patents protect Fibricor?
Fibricor's formulation is a delayed-release tablet designed to deliver fenofibric acid after oral administration. Formulation patents may cover excipient composition, release characteristics, coating systems, particle size or manufacturing parameters.
These claims are narrower than active-ingredient patents. Generic applicants can often avoid infringement by using a different coating composition, release profile within FDA specifications or manufacturing process. The availability of generic fenofibric acid products indicates that the formulation estate does not prevent market entry.
Formulation-related barriers remain more relevant to:
- Bioequivalence testing
- Dissolution-profile matching
- Tablet coating and scale-up
- Stability under commercial packaging conditions
- Manufacturing consistency
They do not provide a durable basis for premium pricing once multiple generic products are approved.
Are there Paragraph IV challenges or Fibricor patent litigation?
The major U.S. patent litigation risk has already been realized through generic entry rather than a current branded defense campaign. Abbreviated new drug application applicants may have used Paragraph IV certifications against listed patents, but Fibricor does not have a current litigation profile comparable to products with active, high-value Orange Book patents.
| Litigation factor |
Fibricor assessment |
| Current high-value Orange Book patents |
Low |
| Ongoing branded patent defense |
No material public program identified |
| Paragraph IV exposure |
Historical and commercially resolved through generic entry |
| 30-month stay relevance |
Limited for current market access |
| Settlement-driven delay |
No material current delay mechanism |
| Generic launch risk |
Already realized |
A Paragraph IV certification can challenge an Orange Book patent by asserting invalidity, unenforceability or noninfringement. For Fibricor, the commercial question is no longer whether generic entry can occur. It is whether a manufacturer can obtain sustainable volume and reimbursement in a crowded generic lipid market.
Which companies compete with Fibricor?
Fibricor competes across three product groups: generic fenofibric acid, generic fenofibrate and non-fibrate triglyceride-lowering products.
How does Fibricor compare with Trilipix and generic fenofibrate?
| Product |
Active ingredient |
Dosage form |
Market position |
| Fibricor |
Fenofibric acid |
Delayed-release tablet |
Brand or legacy product with limited pricing power |
| Trilipix |
Fenofibric acid |
Delayed-release capsule |
Related legacy brand |
| Generic fenofibric acid |
Fenofibric acid |
Tablet or capsule, depending on product |
Direct price competitor |
| Generic fenofibrate |
Fenofibrate |
Multiple oral formulations |
Broad generic competition |
| Vascepa and generics |
Icosapent ethyl |
Capsule |
Competes in elevated triglycerides and cardiovascular-risk management |
| Prescription omega-3 products |
Omega-3 fatty acids |
Capsule |
Competes in severe hypertriglyceridemia |
| Statins |
Several active ingredients |
Oral tablets |
Foundation therapy for atherosclerotic risk |
Fenofibric acid products can be selected when clinicians want a fenofibrate-related therapy with specific dosing or formulation characteristics. In routine practice, price, formulary placement and familiarity with generic fenofibrate often outweigh brand differentiation.
What is the Fibricor market size and revenue outlook?
Public financial disclosures do not generally report Fibricor revenue as a separate material product line. The product is a mature, low-growth prescription medicine competing in a largely generic market. A reliable brand-specific revenue estimate cannot be derived from company filings without transaction-level prescription, payer or channel data.
What drives Fibricor demand?
Demand is tied to several factors:
- Persistent severe hypertriglyceridemia in patients with diabetes, obesity, metabolic syndrome or renal disease.
- Use of fibrates when triglycerides remain high despite lifestyle intervention and statin therapy.
- Prescriber preference for fenofibric acid formulations.
- Insurance coverage and pharmacy substitution.
- Availability of lower-cost generic alternatives.
The market is structurally price-sensitive. Generic substitution reduces the opportunity for Fibricor to maintain a substantial premium unless the product has a differentiated contract, supply position or payer restriction.
Fibricor market projection, 2025-2030
| Scenario |
Expected market direction |
Main assumptions |
| Base case |
Decline or stagnation in branded Fibricor sales |
Generic substitution, stable fibrate use, limited innovation |
| Upside case |
Low-single-digit volume growth but limited revenue growth |
Higher diagnosis of severe hypertriglyceridemia and stable reimbursement |
| Downside case |
Double-digit annual revenue contraction |
Further generic price erosion, formulary exclusion and migration to omega-3 or newer therapies |
The most likely outcome is declining branded revenue with stable or modestly declining category volume. Any growth in the broader triglyceride-lowering market is more likely to accrue to generic products, icosapent ethyl, prescription omega-3 therapies or emerging metabolic medicines than to Fibricor.
What generic entry risks exist for Fibricor?
Generic entry risk is high because the product has:
- A mature active ingredient
- No meaningful current exclusivity advantage
- Established therapeutic equivalence pathways
- Limited brand differentiation
- Substitution-friendly pharmacy economics
- Competition from several low-cost fibrate products
Generic manufacturers may still face technical barriers involving delayed release, dissolution testing and bioequivalence. These are execution risks rather than durable legal barriers.
The most likely generic launch pattern is a low-price initial launch followed by rapid price compression as additional suppliers enter. Wholesaler stocking, Medicaid reimbursement, pharmacy benefit manager contracts and manufacturing reliability will determine commercial share.
How strong is the Fibricor patent estate?
Fibricor has a weak current patent estate from a commercial defense perspective.
| Patent-strength criterion |
Assessment |
| Composition-of-matter protection |
Expired or no longer commercially decisive |
| Formulation protection |
Narrow and subject to design-around |
| Method-of-use protection |
Limited by mature treatment practice and label restrictions |
| Manufacturing protection |
Supplier-specific rather than market-blocking |
| Remaining exclusivity value |
Low |
| Generic litigation leverage |
Low |
| Licensing leverage |
Low |
The main residual IP value may exist in manufacturing know-how, supply agreements, trademarks or jurisdiction-specific rights. None is equivalent to an unexpired composition patent.
Does Fibricor have biosimilar risk?
Fibricor has no biosimilar risk because it is a chemically synthesized small molecule, not a biologic. Its relevant competitive threat is generic-drug substitution.
Biosimilar economics apply to monoclonal antibodies, recombinant proteins and other biologic medicines. Fibricor faces abbreviated new drug application competition under the small-molecule generic pathway.
What manufacturing and geographic barriers affect Fibricor?
Manufacturing barriers are moderate at the technical level and low at the market level. A supplier must control:
- Fenofibric acid API quality
- Particle size and solid-state characteristics
- Delayed-release coating performance
- Dissolution across required media
- Tablet content uniformity
- Stability and packaging
- FDA current good manufacturing practice compliance
Geographic protection is also limited. U.S. patents and FDA approvals govern U.S. market access, while European and other national rights have separate expiry and regulatory histories. Generic fenofibrate and fenofibric acid products are available across multiple jurisdictions, although product names, strengths and approved indications differ.
What licensing deals affect Fibricor?
No major current licensing transaction materially changes the Fibricor outlook. Historical rights, product transfers or commercial arrangements may affect who markets the product, but they do not restore exclusivity after generic entry.
Any potential transaction would be assessed primarily on:
- Net price after rebates
- Remaining prescription volume
- Manufacturing cost
- Supply continuity
- Inventory and recall exposure
- Regulatory obligations
- Trademark value
- Geographic rights
Fibricor is more likely to fit a mature-products portfolio transaction than an innovation-focused licensing deal.
Key Takeaways
- Fibricor is fenofibric acid delayed-release tablets for severe hypertriglyceridemia and mixed dyslipidemia.
- The product has no material active clinical-development program.
- FDA approval supports lipid modification, not cardiovascular-outcomes reduction.
- Generic competition and expired or commercially weak patent protection limit brand value.
- Formulation and manufacturing know-how may create technical hurdles but do not block generic entry.
- Fibricor has no biosimilar risk; its principal threat is generic substitution.
- Branded revenue is likely to stagnate or decline through 2030.
- The broader triglyceride market may grow, but growth is likely to favor generics, icosapent ethyl, prescription omega-3 products and newer metabolic therapies.
FAQs
Is Fibricor the same as fenofibrate?
No. Fibricor contains fenofibric acid, the active metabolite of fenofibrate. The products are pharmacologically related but are not identical formulations.
Can Fibricor be taken with a statin?
The combination may be used in clinical practice, but it requires medical supervision because fibrates and statins can increase the risk of muscle toxicity, particularly in patients with renal impairment or other risk factors.[1]
Is there a generic version of Fibricor?
Yes. Generic fenofibric acid products compete with Fibricor in the U.S. market, subject to FDA approval and product-specific availability.
Does Fibricor prevent heart attacks?
Fibricor is not approved to reduce cardiovascular morbidity or mortality. Its FDA-approved role is lipid management as an adjunct to diet.[1]
What is the main investment risk for Fibricor?
The principal risk is commercial erosion from generic substitution, low pricing power and migration to therapies with stronger cardiovascular-outcomes evidence.
References
- U.S. Food and Drug Administration. (n.d.). Fibricor (fenofibric acid) delayed-release tablets: Prescribing information. FDA.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
- U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. National Institutes of Health.
- U.S. Food and Drug Administration. (2008). FDA approval materials for fenofibric acid delayed-release tablets. FDA.
